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Statins offer remarkable protection against cardiovascular disease, with an acceptablesafetyprofile.1 People 
requiring statins are those at high risk of cardiovascular disease, irrespective of baseline lipid levels.2-4 This 
statement being accepted, two remaining key questions are: how to best stratify risk individually and how 
aggressive statin therapy should be according to baseline individual risk of cardiovascular disease.5
Controversies arose about the benefit-to-risk ratio of lowering cholesterol as much as possible in the absence of a 
high risk of cardiovascular disease,6 on the one hand, and about the meaning of the metabolic syndrome as an 
independent cardiovascular risk factor, on the other.7 In today's Lancet, Prakash Deedwania and colleagues8 add 
an interesting piece of information to this complex debate. In their post-hoc analysis of the Treating to New 
Targets (TNT) study, patients with coronary heart disease and metabolic syndrome benefited from aggressive 
atorvastatin therapy (80 mg instead of 10 mg a day), irrespective of the presence of diabetes. In patients 
receiving a low dose of atorvastatinthe incidence of major cardiovascular events was higher in the presence of 
metabolic syndrome (11.3%; if diabetes excluded, 9.9%) than in the subgroup without metabolic syndrome (8%; 
7.5%  if diabetes excluded). But the incidence remained lower in patients with metabolic syndrome than that in 
the diabetic population (17·9%)· The number needed to treat to avoid a major cardiovascular event over a 5-year 
period with 80 mg versus 10 mg atorvastatin averaged 45 in the whole TNT population;9 it increased up to l67 in 
the subgroup without metabolic syndrome,8 but decreased to 24 in patients with diabetes,10 and to 28 in those 
with metabolic syndrome (without diabetes) (figure).8 Thus focusing  aggressive therapy on  patients with 
metabolic syndrome or diabetes in a population with stable coronary heart disease allows the number needed to 
treat to be reduced substantially, which thus gains a significant improvement in the cost-effectiveness of high 
statin dose. 
Patients with coronary heart disease have, de facto, a high cardiovascular disease risk, making their individual 
risk calculation unnecessary before starting statin therapy.2-5 The key question is not whether a statin should be 
started in these patients, but rather how aggressive the treatment should be. Although acute coronary syndrome 
might justify a high dose of statin,4,5 the risk/benefit of such aggressive approach remains an open question in 
patients with stable coronary heart disease.6 The TNT findings suggest that the presence of metabolic syndrome 
might help to select patients who will best benefit from an aggressive lipid-lowering therapy. In the CASS 
registry in North America, metabolic syndrome also conferred a higher risk of long-term death in patients with 
pre-existing coronary heart disease, and dysglycaemia seemed to be responsible for most of the associated risk.11 
In TNT, univariate analysis of the individual characteristics of metabolic syndrome showed a significant, and 
almost similar, increased risk of major cardiovascular events with the presence of each component of metabolic 
syndrome. Interestingly, the risk of major cardiovascular events increased with the presence of each additional 
component of metabolic syndrome. 
In patients without cardiovascular disease, the decision about starting a statin relies on the calculation of a global 
cardiovascular disease risk, taking into account many classic risk factors, but not some others that form part of 
the metabolic syndrome.2-4 However, in the INTERHEART study, abdominal obesity, a key feature of metabolic 
syndrome, accounted for 44% of the risk of a first myocardial infarction.12 Unfortunately, because waist 
circumference was not measured in TNT, the two most popular definitions of metabolic syndrome (National 
Cholesterol Education Program, International Diabetes Federation) could not be used in their strict sense for the 
analysis. More importantly, the value of metabolic syndrome compared with the Framingham equation for 
individual risk stratification has been challenged in primary prevention.13 In the San Antonio Heart Study, 
metabolic syndrome predicts less effectively the future development of cardiovascular disease than the 
established Framingham risk score, and does not enhance the performance of the Framingham score when 
combined with it.14
The results from TNT lend further support to implementing lower lipid goals than those currently suggested by 
guidelines. However, when treatment with high statin doses is considered, the selection of patients whose risk of 
major cardiovascular events is high enough to outweigh the potential risk of toxic drug-related effects is most 
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important. The two post-hoc analyses of TNT in patients with diabetes and/or metabolic syndrome support the 
concept of the higher the risk, the greater the need to treat and to treat aggressively. This concept, already 
accepted in primary prevention, might be extended to secondary prevention, although such a suggestion requires 
further assessment. 
Figure: Major cardiovascular events in TNT trial 
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Number of major cardiovascular events per number of patients treated with atorvastatin 10 mg (above each arrow) or atorvastatin 80 mg 
(atthe right of each arrow). NNT=number needed to treat, with high instead of low dose of atorvastatin to avoid major cardiovascular events 
over 5-year period in various subgroups. MetS=metabolic syndrome. The first row of numbers above each arrow corresponds to number of 
events per number of patients treated with atorvastatin 10 mg. Numbers at the right of each arrow corresponds to number of events per 
number of patients treated with atorvastatin 
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